WallStreetZenWallStreetZen

NASDAQ: PPCB
Propanc Biopharma Inc Earnings Dates, Reports, Calls

OverviewEarnings
RevenueDividendOwnership
Propanc Biopharma earnings were -$67.0M for the trailing 12 months ending Dec 31, 2025, with -99.1% growth year over year. The latest PPCB earnings report on Dec 31, 2025 announced Q4 2025 earnings of -$4.0M, down 16.8% from last quarter. For the last reported fiscal year 2025 ending Jun 30, 2025, PPCB reported annual earnings of -$58.9M, with 2,826.4% growth.

PPCB past earnings growth

How has PPCB's earnings growth performed historically?

Company
-99.06%
Industry
82.81%
Market
87.86%
PPCB's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
PPCB's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance

PPCB earnings history

Current Revenue
$0.0
Current Earnings
-$67.0M
Current Profit Margin
0%

PPCB Return on Equity

Current Company
-471.7%
Current Industry
-31.4%
Current Market
28.9%
PPCB's Return on Equity (-471.7%)... subscribe to Premium to read more.
High Return on Equity Performance

PPCB Return on Assets

Current Company
-356.2%
Current Industry
-9.6%
PPCB is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when PPCB announces earnings.

PPCB Return on Capital Employed

Current Company
-568.83%
Current Industry
-3.7%
PPCB's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

PPCB vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
PPCB-$65.32M-$67.00M-99.06%$10.58
CNSP-$15.83M-$15.85MN/A-$35.75
ATON-$14.88M-$14.89MN/A-$8.01
HCWB-$6.07M-$22.30MN/A-$10.63
INM-$7.07M-$7.66MN/A-$3.32
View Top Biotech Stocks

Propanc Biopharma Earnings Reports & History FAQ

What were Propanc Biopharma's earnings last quarter?

Propanc Biopharma (NASDAQ: PPCB) reported Q4 2025 earnings per share (EPS) of -$0.30, up 99.07% year over year. Total PPCB earnings for the quarter were -$4.02 million. In the same quarter last year, Propanc Biopharma's earnings per share (EPS) was -$32.23.

If you're new to stock investing, here's how to buy Propanc Biopharma stock.

Is Propanc Biopharma profitable or losing money?

As of the last Propanc Biopharma earnings report, Propanc Biopharma is currently losing money. Propanc Biopharma's net profit (also called net income) for the twelve months ending Dec 31, 2025 was -$66.07 million, a 3,856.71% increase year over year.

What was PPCB's earnings growth in the past year?

As of Propanc Biopharma's earnings date in Q2 2026, Propanc Biopharma's earnings has grown -99.06% year over year. This is 181.87 percentage points lower than the US Biotechnology industry earnings growth rate of 82.81%. PPCB earnings in the past year totalled -$67.00 million.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.